Search Results - "Ricciuti, B."

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer by Lamberti, G., Spurr, L.F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L.M., Meyerson, M.L., Cherniack, A.D., Awad, M.M.

“…Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in…”
Get full text

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E.J., Ricciuti, B., Gainor, J.F., Kehl, K.L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L.M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R.M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K.C., Carter, B.W., Heymach, J.V., Altan, M., Hellmann, M.D., Awad, M.M.

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50 by Gainor, J.F., Rizvi, H., Jimenez Aguilar, E., Skoulidis, F., Yeap, B.Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Zhang, J., Roth, J.A., Grishman, J., Anderson, D., Little, B.P., Carter, B.W., Arbour, K., Sauter, J.L., Mino-Kenudson, M., Heymach, J.V., Digumarthy, S., Shaw, A.T., Awad, M.M., Hellmann, M.D.

“…Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1…”
Get full text

Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy by Cortellini, A., Ricciuti, B., Facchinetti, F., Alessi, J.V.M., Venkatraman, D., Dall'Olio, F.G., Cravero, P., Vaz, V.R., Ottaviani, D., Majem, M., Piedra, A., Sullivan, I., Lee, K.A., Lamberti, G., Hussain, N., Clark, J., Bolina, A., Barba, A., Benitez, J.C., Gorría, T., Mezquita, L., Hoton, D., Aboubakar Nana, F., Besse, B., Awad, M.M., Pinato, D.J.

“…Prior antibiotic therapy (pATB) is known to impair efficacy of single-agent immune checkpoint inhibitors (ICIs), potentially through the induction of gut…”
Get full text

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities by Wang, X, Lamberti, G, Di Federico, A, Alessi, J, Ferrara, R, Sholl, M L, Awad, M M, Vokes, N, Ricciuti, B

“…Tumor mutational burden (TMB) is a biomarker that measures the number of somatic mutations in a tumor's genome. TMB has emerged as a predictor of response to…”
Get more information

A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions by Cortellini, A., Barrichello, A.P.C., Alessi, J.V., Ricciuti, B., Vaz, V.R., Newsom-Davis, T., Evans, J.S., Lamberti, G., Pecci, F., Viola, P., D’Alessio, A., Fulgenzi, C.A.M., Awad, M.M., Pinato, D.J.

Get full text

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma by Scalera, S., Ricciuti, B., Mazzotta, M., Calonaci, N., Alessi, J.V., Cipriani, L., Bon, G., Messina, B., Lamberti, G., Di Federico, A., Pecci, F., Milite, S., Krasniqi, E., Barba, M., Vici, P., Vecchione, A., De Nicola, F., Ciuffreda, L., Goeman, F., Fanciulli, M., Buglioni, S., Pescarmona, E., Sharma, B., Felt, K.D., Lindsay, J., Rodig, S.J., De Maria, R., Caravagna, G., Cappuzzo, F., Ciliberto, G., Awad, M.M., Maugeri-Saccà, M.

“…KEAP1 mutations have been associated with reduced survival in lung adenocarcinoma (LUAD) patients treated with immune checkpoint inhibitors (ICIs),…”
Get full text

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer by Ricciuti, B., Alessi, J.V., Elkrief, A., Wang, X., Cortellini, A., Li, Y.Y., Vaz, V.R., Gupta, H., Pecci, F., Barrichello, A., Lamberti, G., Nguyen, T., Lindsay, J., Sharma, B., Felt, K., Rodig, S.J., Nishino, M., Sholl, L.M., Barbie, D.A., Negrao, M.V., Zhang, J., Cherniack, A.D., Heymach, J.V., Meyerson, M., Ambrogio, C., Jänne, P.A., Arbour, K.C., Pinato, D.J., Skoulidis, F., Schoenfeld, A.J., Awad, M.M., Luo, J.

“…Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous…”
Get full text

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes by Cortellini, A., Leonetti, A., Catino, A., Pizzutillo, P., Ricciuti, B., De Giglio, A., Chiari, R., Bordi, P., Santini, D., Giusti, R., De Tursi, M., Brocco, D., Zoratto, F., Rastelli, F., Citarella, F., Russano, M., Filetti, M., Marchetti, P., Berardi, R., Torniai, M., Cortinovis, D., Sala, E., Maggioni, C., Follador, A., Macerelli, M., Nigro, O., Tuzi, A., Iacono, D., Migliorino, M. R., Banna, G., Porzio, G., Cannita, K., Ferrara, M. G., Bria, E., Galetta, D., Ficorella, C., Tiseo, M.

“…Background In most cases, T790M EGFR -positive NSCLC patients receiving osimertinib developed “non-drugable” progression, as the patients with common EGFR…”
Get full text

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer by Ricciuti, B., Brambilla, M., Cortellini, A., De Giglio, A., Ficorella, C., Sidoni, A., Bellezza, G., Crinò, L., Ludovini, V., Baglivo, S., Metro, G., Chiari, R.

“…Purpose KRAS mutation has been associated with enhanced dependency on the folate metabolism in preclinical studies. However, whether KRAS mutation correlates…”
Get full text

Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels by Ricciuti, B., Chiari, R., Tofanetti, F.R., De Giglio, A., Porreca, R., Brambilla, M., Sperduti, I., Bellezza, G., Mencaroni, C., Siggillino, A., Zicari, D., Baldi, A., Ludovini, V., Metro, G.

Get full text

2198P Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer by Makarem, M., Ricciuti, B., Alessi, J.V., Pecci, F., Di Federico, A., Gandhi, M., Jänne, P.A., Awad, M.M., Rotow, J.K.

Get full text

PO-2125 Contrastive self-supervised learning of lung tumor imaging predicts immunotherapy response by Chaunzwa, T., Pai, S., Bontempi, D., Ricciuti, B., Bernatz, S., Alessi, J., Mak, R., Awad, M., Aerts, H.

Get full text

2255P Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers by Ricciuti, B., Alessi, J.V., Wang, X., Pecci, F., Di Federico, A., Gandhi, M., Makarem, M., Sholl, L., Jänne, P.A., Ambrogio, C., Awad, M.M.

Get full text

1060P Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC by Lamberti, G., Cooper, A.J., Ricciuti, B., Alessi, J.V., de Castro Barrichello, A.P., Pecci, F., Vaz, V.R., Nishino, M., Sholl, L.M., Heist, R., Awad, M.

Get full text

AI-Derived CT Body Composition in Advanced Non-Small Cell Lung Cancer: A Multicohort Study by Chaunzwa, T.L., Qian, J.M., Li, Q., Ricciuti, B., Zhang, Z., Weiss, J., Mackay, J., Kagiampakis, I., Bikiel, D., Federico, A. Di, Alessi, J., Mak, R.H., Jacob, E., Awad, M.M., Aerts, H.

“…The relationship between body composition (BC) and cancer outcomes is complex and incompletely understood. Previous research in non-small cell lung cancer…”
Get full text

182P METHRO: Multicentric study of risk of thrombosis in patients with NSCLC harboring a METexon 14 skipping mutation by Becerra, M.V. Sanchez, Pecci, F., Aldea, M., Ricciuti, B., Garbo, E., Zrafi, W.S., Artahona, V.M. Albarran, Makarem, M., Saini, A., Paoloni, F., Lavaud, P., Frelaut, M., Abdayem, P., Parisi, C., Planchard, D., Barlesi, F., Awad, M., Besse, B., Masip, J. Remon

Get full text

53PImmune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme by Baldini, E, Lunghi, A, Cortesi, E, Turci, D, Garassino, M C, Stati, V, Ardizzoni, A, Ricciuti, B, Frassoldati, A, Romano, G, Illiano, A, Verderame, F, Fasola, G, Marchetti, P, Pinto, C, Carteni, G, Scotti, V, Tibaldi, C, Fioretto, L, Giannarelli, D

Get full text

Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme by Baldini, E., Lunghi, A., Cortesi, E., Turci, D., Garassino, M.C., Stati, V., Ardizzoni, A., Ricciuti, B., Frassoldati, A., Romano, G., Illiano, A., Verderame, F., Fasola, G., Marchetti, P., Pinto, C., Carteni, G., Scotti, V., Tibaldi, C., Fioretto, L., Giannarelli, D.

Get full text

118P Role of PD-L1 and pathological complete response (pCR) with neoadjuvant (NEO) or perioperative (PERIOP) immune-checkpoint inhibitors (ICI) and platinum-based chemotherapy (PCT) in resectable non-small cell lung cancer (NSCLC): A systematic review and metanalysis by Nuccio, A., Viscardi, G., Cameron, R., Salomone, F., Servetto, A., Venanzi, F.M., Riva, S.T., Oresti, S., Ogliari, F.R., Bulotta, A., Ricciuti, B., Marinelli, D., Ferrara, M., Vitiello, F., Cascone, T., Garassino, M.C., Veronesi, G., Torri, V., Cinquini, M., Ferrara, R.

Get full text